Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.53 |
| ▸ | ESR1 | P03372 | 6/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663459 | 0.85 | TRPV1 (0.54) | TRPV1ESR1ESR2GLAKDM4E | |
| SCHEMBL1664029 | 0.81 | TRPV1 (0.62) | TRPV1ESR1ESR2KDM4EMAPT | |
| SCHEMBL1663746 | 0.81 | TRPV1 (0.65) | TRPV1ESR1ESR2MAPTALDH1A1 | |
| SCHEMBL1664030 | 0.79 | TRPV1 (0.57) | TRPV1ESR1ESR2GLAKDM4E | |
| SCHEMBL1662144 | 0.77 | TRPV1 (0.52) | TRPV1ESR1ESR2KDM4EMAPT | |
| SCHEMBL1663398 | 0.76 | TRPV1 (0.72) | TRPV1ESR1ESR2KDM4EALDH1A1 | |
| SCHEMBL10446158 | 0.76 | TRPV1 (0.72) | TRPV1ESR1ESR2KDM4EMAPT | |
| SCHEMBL10446408 | 0.75 | TRPV1 (0.64) | TRPV1ESR1ESR2KDM4EMAPT | |
| SCHEMBL10446403 | 0.75 | TRPV1 (0.64) | TRPV1ESR1ESR2KDM4EMAPT | |
| SCHEMBL10446210 | 0.75 | TRPV1 (0.64) | TRPV1ESR1ESR2GLAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305652-A2 | Trisubstituted quinazolinone derivatives as vanilloid antagonists | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | NOVARTIS AG | 2009-03-26 | — | — | US | disclosed |
| CN-101356160-A | Trisubstituted quinazolinone derivatives as vanilloid antagonists | JANSSEN PHARMACEUTICA NV (CH) | 2009-01-28 | — | — | CN | disclosed |
| EP-1963283-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007065662-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | TRPV1, TRPV3, TRPV5 | TRPV1 1/4885ESR1 1321/4885ESR2 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.